Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort
Havulinna et al. Arterioscler Thromb Vasc Biol. 2016; 36
Read moreCoronary Event Risk Test available in Finland through United Medix Laboratories
Ceramides, Coronary Event Risk Test, CERT Coronary Event Risk Test, CERT, is a new diagnostic test for evaluation of risk of heart attack and CVD-related…
Read moreWe are hiring – Join Zora-team
Zora Biosciences is looking for a Bioinformatician Zora Biosciences Oy is a discovery diagnostics company. Zora identifies, validates and develops novel clinical tools using a…
Read morePlasma Ceramide test is now available at Mayo Clinic Medical Laboratories
Plasma Ceramides predict adverse cardiovascular events. Elevated plasma ceramide concentrations are risk factors for cardiovascular mortality, myocardial infarction and acute coronary syndrome hospitalizations. Plasma ceramides…
Read moreZora and Mayo Medical Laboratories to collaborate on Plasma Ceramide Testing
Zora and Mayo Medical Laboratories has signed Collaborate on Plasma Ceramides Testing. The test will be launched in summer, and is used to predict adverse…
Read moreZora at EAS 2016 Innsbruck
Zora participates 84th EAS Congress at Innsbruck, Austria. Our CMO Reijo Laaksonen presents our latest results on cardiovascular risk prediction in statin treated patients at…
Read moreZora at Nature Reviews Research Highlights
Zora's recent publication on CERT was reviewed in Nature Reviews Cardiology Research Highlights. Read the research highlight here.
Read moreNew biomarker for identification of coronary artery disease patients at high risk for cardiovascular death
Zora Biosciences in collaboration with academic research groups from Finland, Germany, Austria, Switzerland and Norway have shown that plasma ceramides are significant predictors of cardiovascular…
Read moreZora has updated visual identity
We have renewed our visual identity. Zora logo is now modernized. Inspiration for the new logo comes from the six carbon ring that is commonly…
Read morePlasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol
Laaksonen et al. European Heart Journal, Published online: 28 April 2016
Read moreAccumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas
Hilvo et al. Cancer Res. 2016 Feb 15;76(4):796-804
Read moreLipidomics: a tool for studies of atherosclerosis
Ekroos K et al. Curr Atheroscler Rep. 2010 Jul;12(4):273-81
Read moreDevelopment and validation of a high-throughput LC-MS/MS assay for routine measurement of molecular ceramides
Kauhanen D et al. Anal Bioanal Chem. 2016 May;408(13):3475-83
Read moreSTOMPing forward: statins, muscle complaints and CK
Laaksonen R. Atherosclerosis. 2013 Oct;230(2):256-7
Read moreBeyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency
Jänis et al. Atherosclerosis 2013 Jun;228(2):380-5
Read moreIdentifying new Risk Markers and Potential Targets for Coronary Artery Disease: The Value of the Lipidome and Metabolome
Laaksonen R. Cardiovasc Drugs Ther. 2016 Feb;30(1):19-32
Read morePlasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study
Cheng JM et al. Atherosclerosis 2015 Dec;243(2):560-6.
Read moreMolecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency
Tarasov K et al. J Clin Endocrinol Metab. 2014 Jan;99(1):E45-52
Read moreAlcohol produces distinct hepatic lipidome and eicosanoid signature in lean and obese
Puri P et al. J Lipid Res. 2016 Mar 28
Read more